Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 316

1.

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL.

J Clin Oncol. 2019 Feb 4:JCO1801207. doi: 10.1200/JCO.18.01207. [Epub ahead of print]

PMID:
30715997
2.

Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.

Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, Zheng Y, Skakodub A, Mehta SA, Campos C, Hsieh WY, Selcuklu SD, Ling L, Meng F, Jing X, Samoila A, Bale TA, Tsui DWY, Grommes C, Viale A, Souweidane MM, Tabar V, Brennan CW, Reiner AS, Rosenblum M, Panageas KS, DeAngelis LM, Young RJ, Berger MF, Mellinghoff IK.

Nature. 2019 Jan;565(7741):654-658. doi: 10.1038/s41586-019-0882-3. Epub 2019 Jan 23.

PMID:
30675060
3.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT.

Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.

PMID:
30643254
4.

Arterial thromboembolic events preceding the diagnosis of cancer in older persons.

Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Tagawa ST, Panageas KS, DeAngelis LM.

Blood. 2018 Dec 21. pii: blood-2018-06-860874. doi: 10.1182/blood-2018-06-860874. [Epub ahead of print]

PMID:
30578253
5.

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.

Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP, Manne M, Codega P, Campos C, Viale A, Thomas AA, Berger MF, Hatzoglou V, Reiner AS, Panageas KS, DeAngelis LM, Mellinghoff IK.

Blood. 2019 Jan 31;133(5):436-445. doi: 10.1182/blood-2018-09-875732. Epub 2018 Dec 19.

PMID:
30567753
6.

Comprehensive Approach to Diagnosis and Treatment of Newly Diagnosed Primary CNS Lymphoma.

Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT.

Neuro Oncol. 2018 Nov 12. doi: 10.1093/neuonc/noy192. [Epub ahead of print]

PMID:
30418592
7.

BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.

Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, Keedy V, Bielle F, Hofheinz RD, Joly F, Blay JY, Chau I, Puzanov I, Raje NS, Wolf J, DeAngelis LM, Makrutzki M, Riehl T, Pitcher B, Baselga J, Hyman DM.

J Clin Oncol. 2018 Oct 23:JCO2018789990. doi: 10.1200/JCO.2018.78.9990. [Epub ahead of print]

8.

Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.

Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O'Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE.

Blood. 2018 Nov 22;132(21):2240-2248. doi: 10.1182/blood-2018-02-835496. Epub 2018 Sep 27.

9.

Improving outcomes in primary CNS lymphoma.

Graham MS, DeAngelis LM.

Best Pract Res Clin Haematol. 2018 Sep;31(3):262-269. doi: 10.1016/j.beha.2018.07.006. Epub 2018 Jul 21. Review.

PMID:
30213395
10.

Letter to the Editor Regarding "National Trends for Reoperation in Older Patients with Glioblastoma".

Reiner AS, Goldman DA, Diamond EL, DeAngelis LM, Tabar V, Panageas KS.

World Neurosurg. 2018 Sep;117:466. doi: 10.1016/j.wneu.2018.04.156. No abstract available.

PMID:
30149428
11.

Ability of the Khorana score to predict recurrent thromboembolism in cancer patients with ischemic stroke.

Murthy SB, Cushman M, Bobrow D, Kamel H, Merkler AE, Elkind MSV, DeAngelis LM, Navi BB.

J Clin Neurosci. 2018 Nov;57:111-115. doi: 10.1016/j.jocn.2018.08.018. Epub 2018 Aug 23.

PMID:
30145085
12.

Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.

Lin AL, Jonsson P, Tabar V, Yang TJ, Cuaron J, Beal K, Cohen M, Postow M, Rosenblum M, Shia J, DeAngelis LM, Taylor BS, Young RJ, Geer EB.

J Clin Endocrinol Metab. 2018 Oct 1;103(10):3925-3930. doi: 10.1210/jc.2018-01347.

PMID:
30085142
13.

Metastatic Complications of Cancer Involving the Central and Peripheral Nervous Systems.

Mendez JS, DeAngelis LM.

Neurol Clin. 2018 Aug;36(3):579-598. doi: 10.1016/j.ncl.2018.04.011. Epub 2018 Jun 15. Review.

PMID:
30072072
14.

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.

Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, Li D, Bernal Y, Gonen M, Wendel HG, Sadelain M, Brentjens RJ.

Cancer Discov. 2018 Aug;8(8):958-971. doi: 10.1158/2159-8290.CD-17-1319. Epub 2018 Jun 7.

PMID:
29880584
15.

The trials of neuro-oncology clinical research.

DeAngelis LM.

Neuro Oncol. 2018 Jul 5;20(8):1007-1008. doi: 10.1093/neuonc/noy076. No abstract available.

PMID:
29878174
16.

Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.

Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, Wen PY.

Neuro Oncol. 2018 Jun 18;20(7):897-906. doi: 10.1093/neuonc/noy056.

PMID:
29788429
17.

Metabolic Imaging of the Human Brain with Hyperpolarized 13C Pyruvate Demonstrates 13C Lactate Production in Brain Tumor Patients.

Miloushev VZ, Granlund KL, Boltyanskiy R, Lyashchenko SK, DeAngelis LM, Mellinghoff IK, Brennan CW, Tabar V, Yang TJ, Holodny AI, Sosa RE, Guo YW, Chen AP, Tropp J, Robb F, Keshari KR.

Cancer Res. 2018 Jul 15;78(14):3755-3760. doi: 10.1158/0008-5472.CAN-18-0221. Epub 2018 May 16.

PMID:
29769199
18.

New diagnosis of cancer and the risk of subsequent cerebrovascular events.

Navi BB, Howard G, Howard VJ, Zhao H, Judd SE, Elkind MSV, Iadecola C, DeAngelis LM, Kamel H, Okin PM, Gilchrist S, Soliman EZ, Cushman M, Muntner P.

Neurology. 2018 Jun 5;90(23):e2025-e2033. doi: 10.1212/WNL.0000000000005636. Epub 2018 May 4.

PMID:
29728524
19.

Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.

Omuro A, Beal K, McNeill K, Young RJ, Thomas A, Lin X, Terziev R, Kaley TJ, DeAngelis LM, Daras M, Gavrilovic IT, Mellinghoff I, Diamond EL, McKeown A, Manne M, Caterfino A, Patel K, Bavisotto L, Gorman G, Lamson M, Gutin P, Tabar V, Chakravarty D, Chan TA, Brennan CW, Garrett-Mayer E, Karmali RA, Pentsova E.

J Clin Oncol. 2018 Jun 10;36(17):1702-1709. doi: 10.1200/JCO.2017.76.9992. Epub 2018 Apr 23.

PMID:
29683790
20.

Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation.

Scordo M, Morjaria SM, Littmann ER, Bhatia A, Chung HH, Maloy M, DeAngelis LM, Giralt SA, Taur Y, Sauter CS.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1914-1919. doi: 10.1016/j.bbmt.2018.04.013. Epub 2018 Apr 18.

PMID:
29679773
21.

Fertility preservation in primary brain tumor patients.

Stone JB, Kelvin JF, DeAngelis LM.

Neurooncol Pract. 2017 Mar;4(1):40-45. doi: 10.1093/nop/npw005. Epub 2016 Dec 9.

22.

Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab.

Thomas A, Rosenblum M, Karimi S, DeAngelis LM, Omuro A, Kaley TJ.

CNS Oncol. 2018 Jan;7(1):7-13. doi: 10.2217/cns-2017-0025. Epub 2018 Feb 1.

23.

Reply: Arterial Thromboembolism in Non-Hodgkin Lymphoma, as the Presentation of Occult Cancer, and With Cancer Therapies.

Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM.

J Am Coll Cardiol. 2018 Jan 16;71(2):260-262. doi: 10.1016/j.jacc.2017.10.088. No abstract available.

24.

Enoxaparin vs Aspirin in Patients With Cancer and Ischemic Stroke: The TEACH Pilot Randomized Clinical Trial.

Navi BB, Marshall RS, Bobrow D, Singer S, Stone JB, DeSancho MT, DeAngelis LM.

JAMA Neurol. 2018 Mar 1;75(3):379-381. doi: 10.1001/jamaneurol.2017.4211. No abstract available.

25.

Overview of metastatic disease of the central nervous system.

Nolan C, Deangelis LM.

Handb Clin Neurol. 2018;149:3-23. doi: 10.1016/B978-0-12-811161-1.00001-3. Review.

PMID:
29307359
26.

Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review.

Neil EC, DeAngelis LM.

Blood Adv. 2017 Oct 18;1(23):2041-2045. doi: 10.1182/bloodadvances.2017008201. eCollection 2017 Oct 24.

27.

A pilot study of neuropsychological functions, APOE and amyloid imaging in patients with gliomas.

Correa DD, Kryza-Lacombe M, Zhou X, Baser RE, Beattie BJ, Beiene Z, Humm J, DeAngelis LM, Orlow I, Weber W, Osborne J.

J Neurooncol. 2018 Feb;136(3):613-622. doi: 10.1007/s11060-017-2692-5. Epub 2017 Nov 22.

28.

The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.

Mendez JS, Ostrom QT, Gittleman H, Kruchko C, DeAngelis LM, Barnholtz-Sloan JS, Grommes C.

Neuro Oncol. 2018 Apr 9;20(5):687-694. doi: 10.1093/neuonc/nox187.

PMID:
29036697
29.

Novel Considerations in the Approach to Glioblastoma.

Schaff LR, DeAngelis LM.

J Oncol Pract. 2017 Oct;13(10):639-640. doi: 10.1200/JOP.2017.027607. No abstract available.

30.

Long-term outcomes of adult medulloblastoma patients treated with radiotherapy.

De B, Beal K, De Braganca KC, Souweidane MM, Dunkel IJ, Khakoo Y, Gilheeney SW, DeAngelis LM, Menzel P, Patel SH, Wolden SL.

J Neurooncol. 2018 Jan;136(1):95-104. doi: 10.1007/s11060-017-2627-1. Epub 2017 Oct 10.

31.

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.

Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF.

J Neurooncol. 2018 Jan;136(1):79-86. doi: 10.1007/s11060-017-2624-4. Epub 2017 Oct 7.

32.

Increased risk of arterial thromboembolism in older men with breast cancer.

Reiner AS, Navi BB, DeAngelis LM, Panageas KS.

Breast Cancer Res Treat. 2017 Dec;166(3):903-910. doi: 10.1007/s10549-017-4433-z. Epub 2017 Aug 23.

33.

Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors.

Lin X, Fleisher M, Rosenblum M, Lin O, Boire A, Briggs S, Bensman Y, Hurtado B, Shagabayeva L, DeAngelis LM, Panageas KS, Omuro A, Pentsova EI.

Neuro Oncol. 2017 Sep 1;19(9):1248-1254. doi: 10.1093/neuonc/nox066.

34.

Risk of Arterial Thromboembolism in Patients With Cancer.

Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM.

J Am Coll Cardiol. 2017 Aug 22;70(8):926-938. doi: 10.1016/j.jacc.2017.06.047.

35.

Recurrent Thromboembolic Events after Ischemic Stroke in Patients with Primary Brain Tumors.

Parikh NS, Burch JE, Kamel H, DeAngelis LM, Navi BB.

J Stroke Cerebrovasc Dis. 2017 Oct;26(10):2396-2403. doi: 10.1016/j.jstrokecerebrovasdis.2017.05.031. Epub 2017 Jun 21.

36.

Prognostic awareness, prognostic communication, and cognitive function in patients with malignant glioma.

Diamond EL, Prigerson HG, Correa DC, Reiner A, Panageas K, Kryza-Lacombe M, Buthorn J, Neil EC, Miller AM, DeAngelis LM, Applebaum AJ.

Neuro Oncol. 2017 Oct 19;19(11):1532-1541. doi: 10.1093/neuonc/nox117.

37.

Primary CNS Lymphoma.

Grommes C, DeAngelis LM.

J Clin Oncol. 2017 Jul 20;35(21):2410-2418. doi: 10.1200/JCO.2017.72.7602. Epub 2017 Jun 22. Review.

38.

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK.

Cancer Discov. 2017 Sep;7(9):1018-1029. doi: 10.1158/2159-8290.CD-17-0613. Epub 2017 Jun 15.

39.

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.

Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A.

Neuro Oncol. 2017 Oct 1;19(10):1380-1390. doi: 10.1093/neuonc/nox086.

40.

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.

Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA.

Neuro Oncol. 2017 May 1;19(5):625-635. doi: 10.1093/neuonc/nox029. Review.

41.

Reappraising the 2016 WHO classification for diffuse glioma.

Lin AL, DeAngelis LM.

Neuro Oncol. 2017 May 1;19(5):609-610. doi: 10.1093/neuonc/nox003. No abstract available.

42.

Longitudinal analysis of treatment-induced genomic alterations in gliomas.

Erson-Omay EZ, Henegariu O, Omay SB, Harmancı AS, Youngblood MW, Mishra-Gorur K, Li J, Özduman K, Carrión-Grant G, Clark VE, Çağlar C, Bakırcıoğlu M, Pamir MN, Tabar V, Vortmeyer AO, Bilguvar K, Yasuno K, DeAngelis LM, Baehring JM, Moliterno J, Günel M.

Genome Med. 2017 Feb 2;9(1):12. doi: 10.1186/s13073-017-0401-9.

43.

Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.

Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY.

J Neurooncol. 2017 Mar;132(1):181-188. doi: 10.1007/s11060-016-2357-9. Epub 2017 Jan 23.

44.

Frequency and Predictors of Acute Hospitalization Before Death in Patients With Glioblastoma.

Diamond EL, Panageas KS, Dallara A, Pollock A, Applebaum AJ, Carver AC, Pentsova E, DeAngelis LM, Prigerson HG.

J Pain Symptom Manage. 2017 Feb;53(2):257-264. doi: 10.1016/j.jpainsymman.2016.09.008. Epub 2016 Nov 1.

45.

The confused oncologic patient: a rational clinical approach.

Nolan C, DeAngelis LM.

Curr Opin Neurol. 2016 Dec;29(6):789-796. Review.

46.

A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.

Scordo M, Bhatt V, Hsu M, Omuro AM, Matasar MJ, DeAngelis LM, Dahi PB, Moskowitz CH, Giralt SA, Sauter CS.

Biol Blood Marrow Transplant. 2017 Jan;23(1):38-43. doi: 10.1016/j.bbmt.2016.09.024. Epub 2016 Oct 3.

47.

Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.

Avila EK, Chamberlain M, Schiff D, Reijneveld JC, Armstrong TS, Ruda R, Wen PY, Weller M, Koekkoek JA, Mittal S, Arakawa Y, Choucair A, Gonzalez-Martinez J, MacDonald DR, Nishikawa R, Shah A, Vecht CJ, Warren P, van den Bent MJ, DeAngelis LM.

Neuro Oncol. 2017 Jan;19(1):12-21. doi: 10.1093/neuonc/now190. Epub 2016 Sep 20. Review.

48.

Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences.

de la Fuente MI, Haggiagi A, Moul A, Young RJ, Sidani C, Markoe A, Vega F, DeAngelis LM, Lossos IS.

Leuk Lymphoma. 2017 Apr;58(4):882-888. doi: 10.1080/10428194.2016.1218006. Epub 2016 Sep 21.

49.

Correction regarding data on blinatumomab-associated seizures.

Stone JB, DeAngelis LM.

Nat Rev Clin Oncol. 2016 Oct;13(10):650. doi: 10.1038/nrclinonc.2016.134. Epub 2016 Aug 23. No abstract available.

PMID:
27550852
50.

Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid.

Pentsova EI, Shah RH, Tang J, Boire A, You D, Briggs S, Omuro A, Lin X, Fleisher M, Grommes C, Panageas KS, Meng F, Selcuklu SD, Ogilvie S, Distefano N, Shagabayeva L, Rosenblum M, DeAngelis LM, Viale A, Mellinghoff IK, Berger MF.

J Clin Oncol. 2016 Jul 10;34(20):2404-15. doi: 10.1200/JCO.2016.66.6487. Epub 2016 May 9.

Supplemental Content

Loading ...
Support Center